Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome

Journal of Perinatology volume 29, pages S18–S22 (2009)Cite this article

Abstract

Surfactant treatment in preterm infants and term newborns with (acute respiratory distress syndrome) ARDS-like severe respiratory failure has become part of an individualized treatment strategy in many intensive care units around the world. These babies constitute heterogeneous groups of gestational ages, lung maturity, as well as of the underlying disease processes and postnatal interventions. The pathophysiology of respiratory failure in preterm infants is characterized by a combination of primary surfactant deficiency and surfactant inactivation as a result of plasma proteins leaking into the airways from areas of epithelial disruption and injury. Various pre- and postnatal factors, such as exposure to chorioamnionitis, pneumonia, sepsis and asphyxia, induce an injurious inflammatory response in the lungs of preterm infants, which may subsequently affect surfactant function, synthesis and alveolar stability. Surfactant inactivation—and dysfunction—is also a hallmark in newborns with meconium aspiration syndrome (MAS), pneumonia and other disorders affecting the pulmonary function. Although for the majority of suggested indications no data from randomized controlled trials exist, a surfactant replacement that counterbalances surfactant inactivation seems to improve oxygenation and lung function in many babies with ARDS without any apparent negative side effects. Newborns with MAS will definitely benefit from a reduced need for extracorporeal membrane oxygenation (ECMO). Clinical experience seems to justify surfactant treatment in neonates with ARDS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Halliday HL . History of Surfactant from 1980. Biol Neonate 2005; 87: 317–322.

    Article  CAS  PubMed  Google Scholar 

  2. Ramanathan R . Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS. J Perinatol 2006; 26: S51–S56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Robertson B . New targets for surfactant replacement therapy: experimental and clinical aspects. Arch Dis Child Fetal Neonatal Ed 1996; 75: F1–F3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jobe AH . Mechanisms to explain surfactant response. Biol Neonate 2006; 89: 298–302.

    Article  PubMed  Google Scholar 

  5. Speer CP . Role of inflammation in the evolution of bronchopulmonary dysplasia. Drug Discovery Today Dis Mech 2006; 3 (4): 409–414.

    Article  Google Scholar 

  6. Ho NK . Factors affecting responses of infants with respiratory distress syndrome to exogenous surfactant therapy. Singapore Med J 1993; 34 (1): 74–77.

    CAS  PubMed  Google Scholar 

  7. Jobe AH . Pulmonary surfactant therapy. New Engl J Med 1993; 328 (12): 861–868.

    Article  CAS  PubMed  Google Scholar 

  8. Collaborative European Multicenter Study Group. Factors influencing the clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome. Eur J Pediatr 1991; 150: 433–439.

    Article  Google Scholar 

  9. Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller O et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 1992; 89: 13–20.

    CAS  PubMed  Google Scholar 

  10. Speer CP, Gefeller O, Groneck P, Laufkötter E, Roll C, Hanssler L et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 1995; 72: F8–F13.

    Article  CAS  Google Scholar 

  11. Segerer H, Stevens P, Schadow B, Maier R, Kattner E, Schwarz H et al. Surfactant substitution in ventilated very low birth weight infants: factors related to response types. Pediatr Res 1991; 30: 591–596.

    Article  CAS  PubMed  Google Scholar 

  12. Charon A, Taeusch HW, Fitzgibbon C, Smith GB, Treves ST, Phelps DS . Factors associated with surfactant treatment response in infants with severe respiratory distress syndrome. Pediatrics 1998; 83: 348–354.

    Google Scholar 

  13. Lahra MM, Jeffery HE . A fetal response to chorioamnionitis is associated with early survival after preterm birth. Am J Obstet Gynecol 2004; 190: 147–151.

    Article  PubMed  Google Scholar 

  14. Schmidt B, Cao L, Mackensen-Haen S, Kendziorra H, Klingel K, Speer CP . Chorioamnionitis and inflammation of the fetal lung. Am J Obstet Gynecol 2001; 185: 173–177.

    Article  CAS  PubMed  Google Scholar 

  15. Speer CP . Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med 2006; 11 (5): 354–362.

    Article  PubMed  Google Scholar 

  16. Wirbelauer J, Schmidt B, Klingel K, Cao L, Lang F, Speer CP . Serum and glucocorticoid-inducible kinase in pulmonary tissue of preterm fetuses exposed to chorioamnionitis. Neonatology 2007; 93: 257–262.

    Article  PubMed  Google Scholar 

  17. May M, Marx A, Seidenspinner S, Speer CP . Apoptosis and proliferation in lungs of human fetuses exposed to chorioamnionitis. Histopathology 2004; 45: 283–290.

    Article  CAS  PubMed  Google Scholar 

  18. Herting E, Gefeller O, Land M, van Sonderen L Harms K, Robertson B, Members of the Collaborative European Multicenter Study Group. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 2000; 106: 957–996.

    Article  CAS  PubMed  Google Scholar 

  19. Björklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997; 42: 348–355.

    Article  PubMed  Google Scholar 

  20. Ferreira PJ, Bunch TJ, Albertine KH, Carlton DP . Circulating neutrophil concentration and respiratory distress in premature infants. J Pediatr 2000; 136: 466–472.

    Article  CAS  PubMed  Google Scholar 

  21. Jaarsma A, Braaksma MA, Geven WB, van Oeveren W, Bambang Oetomo S . Activation of the inflammatory reaction within minutes after birth in ventilated preterm lambs with neonatal respiratory distress syndrome. Biol Neonate 2004; 86: 1–5.

    Article  CAS  PubMed  Google Scholar 

  22. Turunen R, Nupponen I, Siitonen S, Repo H, Andersson S . Onset of mechanical ventilation is associated with rapid activation of circulating phagocytes in preterm infants. Pediatrics 2006; 117: 448–454.

    Article  PubMed  Google Scholar 

  23. Jobe AH . Commentary on surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Pediatrics 2000; 106: 1135.

    Article  CAS  PubMed  Google Scholar 

  24. Speer CP, Ruess D, Harms K, Herting E, Gefeller O . Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993; 91: 794–799.

    CAS  PubMed  Google Scholar 

  25. Baur FM, Brenner B, Goetze-Speer B, Neu S, Speer CP . Natural porcine surfactant (Curosurf) down-regulates mRNA of tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha type II receptor in lipopolysaccharide-stimulated monocytes. Pediatr Res 1998; 44: 32–36.

    Article  CAS  PubMed  Google Scholar 

  26. Speer CP, Robertson B, Halliday HL . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr 2000; 89: 510–512.

    Article  CAS  PubMed  Google Scholar 

  27. Rauprich P, Möller O, Walter G, Herting E, Robertson B . Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period. Clin Diagn Lab Immunol 2000; 7: 817–822.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Speer CP, Harms K, Herting E, Neumann N, Curstedt T, Robertson B . Early versus late surfactant replacement therapy in severe respiratory distress syndrome. Lung 1990; 168 (Suppl): 870–876.

    Article  PubMed  Google Scholar 

  29. Pandit PB, Dunn MS, Colucci EA . Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 1995; 95: 32–36.

    CAS  PubMed  Google Scholar 

  30. Pandit PB, Dunn MS, Kelly EN, Perlman M . Surfactant replacement in neonates with early chronic lung disease. Pediatrics 1995; 95: 851–854.

    CAS  PubMed  Google Scholar 

  31. Dargaville PA, South M, McDougall PN . Surfactant and surfactant inhibitors in meconium aspiration syndrome. J Pediatr 2001; 138: 113–115.

    Article  CAS  PubMed  Google Scholar 

  32. Dargaville PA, Copnell B, For the Australian and New Zealand neonatal network. The epidemiology of meconium aspiration syndrome: incidence, risk factors, therapies and outcome. Pediatrics 2006; 117: 1712–1721.

    Article  PubMed  Google Scholar 

  33. Sun B, Curstedt T, Robertson B . Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 1993; 82: 182–189.

    Article  CAS  PubMed  Google Scholar 

  34. Sun B, Herting E, Curstedt T, Robertson B . Exogenous surfactant improves lung compliance and oxygenation in adult rats with meconium aspiration. J Appl Physiol 1994; 77: 1961–1971.

    Article  CAS  PubMed  Google Scholar 

  35. Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B . Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res 2001; 50: 44–49.

    Article  CAS  PubMed  Google Scholar 

  36. Findlay R, Taeusch HW, Walther FJ . Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97: 48–52.

    CAS  PubMed  Google Scholar 

  37. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH . Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 1998; 132: 40–47.

    Article  CAS  PubMed  Google Scholar 

  38. Chinese Collaborative Study Group for Neonatal Respiratory Disease. Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatr 2005; 94: 896–902.

    Article  Google Scholar 

  39. El Shahed AI, Dargaville P, Ohlsson A, Soll RF . Surfactant for meconium aspiration syndrome in full term/near term infants. The Cochrane Library 2007; 3, Art. No. CD002054.

  40. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL . Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991; 87: 101–107.

    CAS  PubMed  Google Scholar 

  41. Khammash H, Perlman M, Wojtulewicz J, Dunn M . Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993; 92: 135–139.

    CAS  PubMed  Google Scholar 

  42. Ogawa Y, Ohama Y, Itakura Y . Bonchial lavage with surfactant solution for the treatment of meconium aspiration syndrome. J Jpn Med Soc Biol Interface 1996; 26: 179–184.

    Google Scholar 

  43. Lam BCC, Yeung CY . Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics 1999; 103: 1014–1018.

    Article  CAS  PubMed  Google Scholar 

  44. Lista G, Bianchi S, Castoldi F, Fontana P, Cavigioli F . Bronchoalveolar lavage with diluted porcine surfactant in mechanically ventilated term infants with meconium aspiration syndrome. Clin Drug Invest 2006; 26: 13–19.

    Article  CAS  Google Scholar 

  45. Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF et al. A multicenter, randomized, controlled trial comparing surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002; 109: 1081–1087.

    Article  PubMed  Google Scholar 

  46. Kattwinkel J . Surfactant lavage for meconium aspiration: a word of caution. Pediatrics 2002; 109: 1167–1168.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Children's Hospital, Würzburg, Germany

    J Wirbelauer & C P Speer

Authors
  1. J Wirbelauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C P Speer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C P Speer.

Additional information

Presented at the Fifth Annual Evidence vs Experience in Neonatal Practices meeting, June 2008, Chicago, Illinois.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirbelauer, J., Speer, C. The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome. J Perinatol 29 (Suppl 2), S18–S22 (2009). https://doi.org/10.1038/jp.2009.30

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jp.2009.30

Keywords

This article is cited by

Search

Advanced search

Quick links